1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Age-related Macular Degeneration Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1.2.2 Wet AMD 1.2.3 Dry AMD 1.3 Market by Application 1.3.1 Global Age-related Macular Degeneration Market Growth Rate by Application: 2017 VS 2021 VS 2028 1.3.2 Drugstore 1.3.3 Hospital 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Market Perspective 2.1 Global Age-related Macular Degeneration Market Size (2017-2028) 2.2 Age-related Macular Degeneration Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028 2.3 Global Age-related Macular Degeneration Market Size by Region (2017-2022) 2.4 Global Age-related Macular Degeneration Market Size Forecast by Region (2023-2028) 2.5 Global Top Age-related Macular Degeneration Countries Ranking by Market Size 3 Age-related Macular Degeneration Competitive by Company 3.1 Global Age-related Macular Degeneration Revenue by Players 3.1.1 Global Age-related Macular Degeneration Revenue by Players (2017-2022) 3.1.2 Global Age-related Macular Degeneration Market Share by Players (2017-2022) 3.2 Global Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Company Covered: Ranking by Age-related Macular Degeneration Revenue 3.4 Global Age-related Macular Degeneration Market Concentration Ratio 3.4.1 Global Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Age-related Macular Degeneration Revenue in 2021 3.5 Global Age-related Macular Degeneration Key Players Head office and Area Served 3.6 Key Players Age-related Macular Degeneration Product Solution and Service 3.7 Date of Enter into Age-related Macular Degeneration Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Global Age-related Macular Degeneration Breakdown Data by Type 4.1 Global Age-related Macular Degeneration Historic Revenue by Type (2017-2022) 4.2 Global Age-related Macular Degeneration Forecasted Revenue by Type (2023-2028) 5 Global Age-related Macular Degeneration Breakdown Data by Application 5.1 Global Age-related Macular Degeneration Historic Market Size by Application (2017-2022) 5.2 Global Age-related Macular Degeneration Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Age-related Macular Degeneration Revenue by Company (2020-2022) 6.2 North America Age-related Macular Degeneration Revenue by Type (2017-2028) 6.3 North America Age-related Macular Degeneration Revenue by Application (2017-2028) 6.4 North America Age-related Macular Degeneration Revenue by Country (2017-2028) 6.4.1 U.S. 6.4.2 Canada 7 Europe 7.1 Europe Age-related Macular Degeneration Revenue by Company (2020-2022) 7.2 Europe Age-related Macular Degeneration Revenue by Type (2017-2028) 7.3 Europe Age-related Macular Degeneration Revenue by Application (2017-2028) 7.4 Europe Age-related Macular Degeneration Revenue by Country (2017-2028) 7.4.1 Germany 7.4.2 France 7.4.3 U.K. 7.4.4 Italy 7.4.5 Russia 8 Asia Pacific 8.1 Asia Pacific Age-related Macular Degeneration Revenue by Company (2020-2022) 8.2 Asia Pacific Age-related Macular Degeneration Revenue by Type (2017-2028) 8.3 Asia Pacific Age-related Macular Degeneration Revenue by Application (2017-2028) 8.4 Asia Pacific Age-related Macular Degeneration Revenue by Region (2017-2028) 8.4.1 China 8.4.2 Japan 8.4.3 South Korea 8.4.4 India 8.4.5 Australia 8.4.6 Taiwan 8.4.7 Indonesia 8.4.8 Thailand 8.4.9 Malaysia 8.4.10 Philippines 8.4.11 Vietnam 9 Latin America 9.1 Latin America Age-related Macular Degeneration Revenue by Company (2020-2022) 9.2 Latin America Age-related Macular Degeneration Revenue by Type (2017-2028) 9.3 Latin America Age-related Macular Degeneration Revenue by Application (2017-2028) 9.4 Latin America Age-related Macular Degeneration Revenue by Country (2017-2028) 9.4.1 Mexico 9.4.2 Brazil 9.4.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Age-related Macular Degeneration Revenue by Company (2020-2022) 10.2 Middle East and Africa Age-related Macular Degeneration Revenue by Type (2017-2028) 10.3 Middle East and Africa Age-related Macular Degeneration Revenue by Application (2017-2028) 10.4 Middle East and Africa Age-related Macular Degeneration Revenue by Country (2017-2028) 10.4.1 Turkey 10.4.2 Saudi Arabia 10.4.3 U.A.E 11 Company Profiles 11.1 Bayer HealthCare 11.1.1 Bayer HealthCare Company Details 11.1.2 Bayer HealthCare Business Overview 11.1.3 Bayer HealthCare Age-related Macular Degeneration Products and Services 11.1.4 Bayer HealthCare Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.1.5 Bayer HealthCare Age-related Macular Degeneration SWOT Analysis 11.1.6 Bayer HealthCare Recent Developments 11.2 F. Hoffmann-La Roche 11.2.1 F. Hoffmann-La Roche Company Details 11.2.2 F. Hoffmann-La Roche Business Overview 11.2.3 F. Hoffmann-La Roche Age-related Macular Degeneration Products and Services 11.2.4 F. Hoffmann-La Roche Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.2.5 F. Hoffmann-La Roche Age-related Macular Degeneration SWOT Analysis 11.2.6 F. Hoffmann-La Roche Recent Developments 11.3 Novartis 11.3.1 Novartis Company Details 11.3.2 Novartis Business Overview 11.3.3 Novartis Age-related Macular Degeneration Products and Services 11.3.4 Novartis Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.3.5 Novartis Age-related Macular Degeneration SWOT Analysis 11.3.6 Novartis Recent Developments 11.4 Regeneron Pharmaceuticals 11.4.1 Regeneron Pharmaceuticals Company Details 11.4.2 Regeneron Pharmaceuticals Business Overview 11.4.3 Regeneron Pharmaceuticals Age-related Macular Degeneration Products and Services 11.4.4 Regeneron Pharmaceuticals Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.4.5 Regeneron Pharmaceuticals Age-related Macular Degeneration SWOT Analysis 11.4.6 Regeneron Pharmaceuticals Recent Developments 11.5 Alcon 11.5.1 Alcon Company Details 11.5.2 Alcon Business Overview 11.5.3 Alcon Age-related Macular Degeneration Products and Services 11.5.4 Alcon Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.5.5 Alcon Age-related Macular Degeneration SWOT Analysis 11.5.6 Alcon Recent Developments 11.6 Allergan 11.6.1 Allergan Company Details 11.6.2 Allergan Business Overview 11.6.3 Allergan Age-related Macular Degeneration Products and Services 11.6.4 Allergan Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.6.5 Allergan Age-related Macular Degeneration SWOT Analysis 11.6.6 Allergan Recent Developments 11.7 Avalanche 11.7.1 Avalanche Company Details 11.7.2 Avalanche Business Overview 11.7.3 Avalanche Age-related Macular Degeneration Products and Services 11.7.4 Avalanche Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.7.5 Avalanche Age-related Macular Degeneration SWOT Analysis 11.7.6 Avalanche Recent Developments 11.8 Bausch+Lomb 11.8.1 Bausch+Lomb Company Details 11.8.2 Bausch+Lomb Business Overview 11.8.3 Bausch+Lomb Age-related Macular Degeneration Products and Services 11.8.4 Bausch+Lomb Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.8.5 Bausch+Lomb Age-related Macular Degeneration SWOT Analysis 11.8.6 Bausch+Lomb Recent Developments 11.9 Gilead Sciences 11.9.1 Gilead Sciences Company Details 11.9.2 Gilead Sciences Business Overview 11.9.3 Gilead Sciences Age-related Macular Degeneration Products and Services 11.9.4 Gilead Sciences Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.9.5 Gilead Sciences Age-related Macular Degeneration SWOT Analysis 11.9.6 Gilead Sciences Recent Developments 11.10 Iconic Therapeutics 11.10.1 Iconic Therapeutics Company Details 11.10.2 Iconic Therapeutics Business Overview 11.10.3 Iconic Therapeutics Age-related Macular Degeneration Products and Services 11.10.4 Iconic Therapeutics Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.10.5 Iconic Therapeutics Age-related Macular Degeneration SWOT Analysis 11.10.6 Iconic Therapeutics Recent Developments 11.11 Neurotech Pharmaceuticals 11.11.1 Neurotech Pharmaceuticals Company Details 11.11.2 Neurotech Pharmaceuticals Business Overview 11.11.3 Neurotech Pharmaceuticals Age-related Macular Degeneration Products and Services 11.11.4 Neurotech Pharmaceuticals Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.11.5 Neurotech Pharmaceuticals Recent Developments 11.12 Ohr Pharmaceutical 11.12.1 Ohr Pharmaceutical Company Details 11.12.2 Ohr Pharmaceutical Business Overview 11.12.3 Ohr Pharmaceutical Age-related Macular Degeneration Products and Services 11.12.4 Ohr Pharmaceutical Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) 11.12.5 Ohr Pharmaceutical Recent Developments 12 Age-related Macular Degeneration Market Dynamics 12.1 Age-related Macular Degeneration Market Trends 12.2 Age-related Macular Degeneration Market Drivers 12.3 Age-related Macular Degeneration Market Challenges 12.4 Age-related Macular Degeneration Market Restraints 13 Research Findings and Conclusion 14 Appendix 14.1 Research Methodology 14.1.1 Methodology/Research Approach 14.1.2 Data Source 14.2 Author Details

List of Tables Table 1. Global Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Wet AMD Table 3. Key Players of Dry AMD Table 4. Global Age-related Macular Degeneration Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 5. Global Age-related Macular Degeneration Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028 Table 6. Global Age-related Macular Degeneration Revenue by Region (2017-2022) & (US$ Million) Table 7. Global Age-related Macular Degeneration Revenue Market Share by Region (2017-2022) Table 8. Global Age-related Macular Degeneration Revenue by Players (2017-2022) & (US$ Million) Table 9. Global Age-related Macular Degeneration Market Share by Players (2017-2022) Table 10. Global Top Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-related Macular Degeneration as of 2021) Table 11. Ranking of Global Top Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2021 Table 12. Global 5 Largest Players Market Share by Age-related Macular Degeneration Revenue (CR5 and HHI) & (2017-2022) Table 13. Key Players Headquarters and Area Served Table 14. Key Players Age-related Macular Degeneration Product Solution and Service Table 15. Date of Key Manufacturers Enter into Age-related Macular Degeneration Market Table 16. Mergers & Acquisitions, Expansion Plans Table 17. Global Age-related Macular Degeneration Market Size by Type (2017-2022) & (US$ Million) Table 18. Global Age-related Macular Degeneration Revenue Market Share by Type (2017-2022) Table 19. Global Age-related Macular Degeneration Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 20. Global Age-related Macular Degeneration Revenue Market Share by Type (2023-2028) Table 21. Global Age-related Macular Degeneration Market Size by Application (2017-2022) & (US$ Million) Table 22. Global Age-related Macular Degeneration Revenue Market Share by Application (2017-2022) Table 23. Global Age-related Macular Degeneration Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 24. Global Age-related Macular Degeneration Revenue Market Share by Application (2023-2028) Table 25. North America Age-related Macular Degeneration Revenue by Company (2020-2022) & (US$ Million) Table 26. North America Age-related Macular Degeneration Revenue by Type (2017-2022) & (US$ Million) Table 27. North America Age-related Macular Degeneration Revenue by Type (2023-2028) & (US$ Million) Table 28. North America Age-related Macular Degeneration Revenue by Application (2017-2022) & (US$ Million) Table 29. North America Age-related Macular Degeneration Revenue by Application (2023-2028) & (US$ Million) Table 30. North America Age-related Macular Degeneration Revenue by Country (2017-2022) & (US$ Million) Table 31. North America Age-related Macular Degeneration Revenue by Country (2023-2028) & (US$ Million) Table 32. Europe Age-related Macular Degeneration Revenue by Company (2020-2022) & (US$ Million) Table 33. Europe Age-related Macular Degeneration Revenue by Type (2017-2022) & (US$ Million) Table 34. Europe Age-related Macular Degeneration Revenue by Type (2023-2028) & (US$ Million) Table 35. Europe Age-related Macular Degeneration Revenue by Application (2017-2022) & (US$ Million) Table 36. Europe Age-related Macular Degeneration Revenue by Application (2023-2028) & (US$ Million) Table 37. Europe Age-related Macular Degeneration Revenue by Country (2017-2022) & (US$ Million) Table 38. Europe Age-related Macular Degeneration Revenue by Country (2023-2028) & (US$ Million) Table 39. Asia Pacific Age-related Macular Degeneration Revenue by Company (2020-2022) & (US$ Million) Table 40. Asia Pacific Age-related Macular Degeneration Revenue by Type (2017-2022) & (US$ Million) Table 41. Asia Pacific Age-related Macular Degeneration Revenue by Type (2023-2028) & (US$ Million) Table 42. Asia Pacific Age-related Macular Degeneration Revenue by Application (2017-2022) & (US$ Million) Table 43. Asia Pacific Age-related Macular Degeneration Revenue by Application (2023-2028) & (US$ Million) Table 44. Asia Pacific Age-related Macular Degeneration Revenue by Region (2017-2022) & (US$ Million) Table 45. Asia Pacific Age-related Macular Degeneration Revenue by Region (2023-2028) & (US$ Million) Table 46. Latin America Age-related Macular Degeneration Revenue by Company (2020-2022) & (US$ Million) Table 47. Latin America Age-related Macular Degeneration Revenue by Type (2017-2022) & (US$ Million) Table 48. Latin America Age-related Macular Degeneration Revenue by Type (2023-2028) & (US$ Million) Table 49. Latin America Age-related Macular Degeneration Revenue by Application (2017-2022) & (US$ Million) Table 50. Latin America Age-related Macular Degeneration Revenue by Application (2023-2028) & (US$ Million) Table 51. Latin America Age-related Macular Degeneration Revenue by Country (2017-2022) & (US$ Million) Table 52. Latin America Age-related Macular Degeneration Revenue by Country (2023-2028) & (US$ Million) Table 53. Middle East and Africa Age-related Macular Degeneration Revenue by Company (2020-2022) & (US$ Million) Table 54. Middle East and Africa Age-related Macular Degeneration Revenue by Type (2017-2022) & (US$ Million) Table 55. Middle East and Africa Age-related Macular Degeneration Revenue by Type (2023-2028) & (US$ Million) Table 56. Middle East and Africa Age-related Macular Degeneration Revenue by Application (2017-2022) & (US$ Million) Table 57. Middle East and Africa Age-related Macular Degeneration Revenue by Application (2023-2028) & (US$ Million) Table 58. Middle East and Africa Age-related Macular Degeneration Revenue by Country (2017-2022) & (US$ Million) Table 59. Middle East and Africa Age-related Macular Degeneration Revenue by Country (2023-2028) & (US$ Million) Table 60. Bayer HealthCare Company Details Table 61. Bayer HealthCare Business Overview Table 62. Bayer HealthCare Age-related Macular Degeneration Product and Services Table 63. Bayer HealthCare Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 64. Bayer HealthCare Age-related Macular Degeneration SWOT Analysis Table 65. Bayer HealthCare Recent Developments Table 66. F. Hoffmann-La Roche Company Details Table 67. F. Hoffmann-La Roche Business Overview Table 68. F. Hoffmann-La Roche Age-related Macular Degeneration Product and Services Table 69. F. Hoffmann-La Roche Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 70. F. Hoffmann-La Roche Age-related Macular Degeneration SWOT Analysis Table 71. F. Hoffmann-La Roche Recent Developments Table 72. Novartis Company Details Table 73. Novartis Business Overview Table 74. Novartis Age-related Macular Degeneration Product and Services Table 75. Novartis Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 76. Novartis Age-related Macular Degeneration SWOT Analysis Table 77. Novartis Recent Developments Table 78. Regeneron Pharmaceuticals Company Details Table 79. Regeneron Pharmaceuticals Business Overview Table 80. Regeneron Pharmaceuticals Age-related Macular Degeneration Product and Services Table 81. Regeneron Pharmaceuticals Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 82. Regeneron Pharmaceuticals Age-related Macular Degeneration SWOT Analysis Table 83. Regeneron Pharmaceuticals Recent Developments Table 84. Alcon Company Details Table 85. Alcon Business Overview Table 86. Alcon Age-related Macular Degeneration Product and Services Table 87. Alcon Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 88. Alcon Age-related Macular Degeneration SWOT Analysis Table 89. Alcon Recent Developments Table 90. Allergan Company Details Table 91. Allergan Business Overview Table 92. Allergan Age-related Macular Degeneration Product and Services Table 93. Allergan Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 94. Allergan Age-related Macular Degeneration SWOT Analysis Table 95. Allergan Recent Developments Table 96. Avalanche Company Details Table 97. Avalanche Business Overview Table 98. Avalanche Age-related Macular Degeneration Product and Services Table 99. Avalanche Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 100. Avalanche Age-related Macular Degeneration SWOT Analysis Table 101. Avalanche Recent Developments Table 102. Bausch+Lomb Company Details Table 103. Bausch+Lomb Business Overview Table 104. Bausch+Lomb Age-related Macular Degeneration Product and Services Table 105. Bausch+Lomb Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 106. Bausch+Lomb Age-related Macular Degeneration SWOT Analysis Table 107. Bausch+Lomb Recent Developments Table 108. Gilead Sciences Company Details Table 109. Gilead Sciences Business Overview Table 110. Gilead Sciences Age-related Macular Degeneration Product and Services Table 111. Gilead Sciences Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 112. Gilead Sciences Age-related Macular Degeneration SWOT Analysis Table 113. Gilead Sciences Recent Developments Table 114. Iconic Therapeutics Company Details Table 115. Iconic Therapeutics Business Overview Table 116. Iconic Therapeutics Age-related Macular Degeneration Product and Services Table 117. Iconic Therapeutics Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 118. Iconic Therapeutics Age-related Macular Degeneration SWOT Analysis Table 119. Iconic Therapeutics Recent Developments Table 120. Neurotech Pharmaceuticals Company Details Table 121. Neurotech Pharmaceuticals Business Overview Table 122. Neurotech Pharmaceuticals Age-related Macular Degeneration Product and Services Table 123. Neurotech Pharmaceuticals Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 124. Neurotech Pharmaceuticals Recent Developments Table 125. Ohr Pharmaceutical Company Details Table 126. Ohr Pharmaceutical Business Overview Table 127. Ohr Pharmaceutical Age-related Macular Degeneration Product and Services Table 128. Ohr Pharmaceutical Age-related Macular Degeneration Revenue in Age-related Macular Degeneration Business (2017-2022) & (US$ Million) Table 129. Ohr Pharmaceutical Recent Developments Table 130. Age-related Macular Degeneration Market Trends Table 131. Age-related Macular Degeneration Market Drivers Table 132. Age-related Macular Degeneration Market Challenges Table 133. Age-related Macular Degeneration Market Restraints Table 134. Research Programs/Design for This Report Table 135. Key Data Information from Secondary Sources Table 136. Key Data Information from Primary Sources List of Figures Figure 1. Global Age-related Macular Degeneration Sales Market Share by Type: 2021 VS 2028 Figure 2. Wet AMD Features Figure 3. Dry AMD Features Figure 4. Global Age-related Macular Degeneration Sales Market Share by Application: 2021 VS 2028 Figure 5. Drugstore Case Studies Figure 6. Hospital Case Studies Figure 7. Others Case Studies Figure 8. Age-related Macular Degeneration Report Years Considered Figure 9. Global Age-related Macular Degeneration Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 10. Global Age-related Macular Degeneration Market Size 2017-2028 (US$ Million) Figure 11. Global Age-related Macular Degeneration Market Size Market Share by Region: 2021 VS 2028 Figure 12. Global Age-related Macular Degeneration Revenue Market Share by Region in 2017 VS 2022 Figure 13. Global Top 10 Age-related Macular Degeneration Countries Ranking by Market Size (US$ Million) in 2021 Figure 14. Global Age-related Macular Degeneration Market Share by Players in 2021 Figure 15. Global Top Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-related Macular Degeneration as of 2021) Figure 16. The Top 10 and 5 Players Market Share by Age-related Macular Degeneration Revenue in 2021 Figure 17. North America Age-related Macular Degeneration Revenue Market Share by Company in 2021 Figure 18. North America Age-related Macular Degeneration Revenue Market Share by Type (2017-2028) Figure 19. North America Age-related Macular Degeneration Revenue Market Share by Application (2017-2028) Figure 20. North America Age-related Macular Degeneration Revenue Share by Country (2017-2028) Figure 21. U.S. Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 22. Canada Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 23. Europe Age-related Macular Degeneration Revenue Market Share by Company in 2021 Figure 24. Europe Age-related Macular Degeneration Revenue Market Share by Type (2017-2028) Figure 25. Europe Age-related Macular Degeneration Revenue Market Share by Application (2017-2028) Figure 26. Europe Age-related Macular Degeneration Revenue Share by Country (2017-2028) Figure 27. Germany Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 28. France Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 29. U.K. Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 30. Italy Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 31. Russia Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 32. Asia Pacific Age-related Macular Degeneration Revenue Market Share by Company in 2021 Figure 33. Asia Pacific Age-related Macular Degeneration Revenue Market Share by Type (2017-2028) Figure 34. Asia Pacific Age-related Macular Degeneration Revenue Market Share by Application (2017-2028) Figure 35. Asia Pacific Age-related Macular Degeneration Revenue Share by Region (2017-2028) Figure 36. China Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 37. Japan Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 38. South Korea Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 39. India Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 40. Australia Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 41. Taiwan Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 42. Indonesia Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 43. Thailand Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 44. Malaysia Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 45. Philippines Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 46. Vietnam Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 47. Latin America Age-related Macular Degeneration Revenue Market Share by Company in 2021 Figure 48. Latin America Age-related Macular Degeneration Revenue Market Share by Type (2017-2028) Figure 49. Latin America Age-related Macular Degeneration Revenue Market Share by Application (2017-2028) Figure 50. Latin America Age-related Macular Degeneration Revenue Share by Country (2017-2028) Figure 51. Mexico Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 52. Brazil Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 53. Argentina Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 54. Middle East and Africa Age-related Macular Degeneration Revenue Market Share by Company in 2021 Figure 55. Middle East and Africa Age-related Macular Degeneration Revenue Market Share by Type (2017-2028) Figure 56. Middle East and Africa Age-related Macular Degeneration Revenue Market Share by Application (2017-2028) Figure 57. Middle East and Africa Age-related Macular Degeneration Revenue Share by Country (2017-2028) Figure 58. Turkey Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 59. Saudi Arabia Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 60. U.A.E Age-related Macular Degeneration Revenue (2017-2028) & (US$ Million) Figure 61. Bayer HealthCare Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 62. F. Hoffmann-La Roche Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 63. Novartis Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 64. Regeneron Pharmaceuticals Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 65. Alcon Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 66. Allergan Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 67. Avalanche Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 68. Bausch+Lomb Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 69. Gilead Sciences Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 70. Iconic Therapeutics Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 71. Neurotech Pharmaceuticals Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 72. Ohr Pharmaceutical Revenue Growth Rate in Age-related Macular Degeneration Business (2017-2022) Figure 73. Bottom-up and Top-down Approaches for This Report Figure 74. Data Triangulation Figure 75. Key Executives Interviewed

Bayer HealthCare F. Hoffmann-La Roche Novartis Regeneron Pharmaceuticals Alcon Allergan Avalanche Bausch+Lomb Gilead Sciences Iconic Therapeutics Neurotech Pharmaceuticals Ohr Pharmaceutical